Scroll Down

  • Home

  • >
  • About Heuron

  • >
  • About us

Our Story

AI for Sustainable Happiness

Our brains have the power to create anything
and also to disrupt anything in our daily lives.
Heuron was established to find faster and more accurate solutions
to the most complex and challenging neurological disorders.
From acute emergencies to neurodegenerative conditions,
we ensure sustainable solutions through innovative AI technology.

Brain disorders should not become
obstacles in our lives.
Everyone should enjoy a beautiful,
fulfilling life.

Brain
New Life,

Together.

Vision
& Mission
Key
Milestones
  • Vision

    Heuron safeguards
    brain health,
    the cornerstone of
    sustainable living
    for you and your loved ones.

  • Mission

    Heuron contributes
    to the diagnosis
    and treatment of
    neurological disorders
    using the power of AI.

Heuron,
an AI healthcare company

led by a neurologist.

Heuron has implemented diagnostic algorithms designed by clinical experts
into AI models, offering rapid and accurate solutions.

  • 2024

    Dec

    Published research paper in AJNR
    (Heuron IPD & Heuron NI)

  • Nov

    Obtained Taiwan FDA clearance for
    Automated Stroke Analysis Software
    (Heuron StroCare Suite™)

  • Oct

    Obtained Taiwan FDA clearance for
    Parkinson’s Disease Analysis Software
    (Heuron IPD)
    MFDS Class 2 approval for Neuromelanin
    Quantification Software
    (Heuron NM)

  • Aug

    Signed distributor agreement with
    Medhealth Informatics, Thailand
    (Heuron StroCare Suite™
    & Heuron AgingCare Suite™)
    Signed research agreement with Siriraj
    Hospital, Mahidol University, Thailand
    (Heuron IPD & Heuron NI)
    Signed research agreement with BDMS,
    Thailand (Heuron AD)
    Signed MOU with Ambulance Dispatch Platform, 'Goochoori' Obtained Taiwan FDA clearance for Brain
    Atrophy Analysis Software (Heuron AD)
    Published research paper in Frontiers in
    Aging Neuroscience, in collaboration with
    Singapore General Hospital
    (Heuron IPD & Heuron NI)

  • Jun

    Launched mobile app for Stroke Triage
    Software (Heuron StroCare Suite™)

  • May

    Signed distributor agreement with Chilli Enterprise, Taiwan Obtained FDA 510(k) Clearance for Stroke Triage SW
    (Heuron ICH)
    Signed research agreement with Tsinghua University, China ISMRM Challenge Finalist

  • Apr

    Signed distributor agreement with Progressive Group, Taiwan

  • Mar

    Signed research agreement with the National University Hospital of Singapore Established Singapore corporation Appoint Stroke Triage SW as Breakthrough Technology
    (Heuron StroCare Suite™)

  • Jan

    Signed MOU with Siemens Healthineers Signed MOU with University Hospital Göttingen, Germany

  • 2023

    Dec

    Stroke Triage SW designated as the 56th Innovative Medical Device
    (Heuron StroCare Suite™)

  • Nov

    MFDS Class 2 approval for CT Perfusion SW for Stroke
    (Heuron CTP)
    Winner of the 2023 Republic of Korea Invention Patent Grand Prize, awarded by the Commissioner of the Korean Intellectual Property Office

  • Oct

    FDA 510k Clearance for Dementia SW
    (Veuron-Brain-pAb3)

  • Jun

    Certified for GDPR, HIPAA, CSA-STAR MFDS Class 3 approval for Stroke Triage SW
    (Heuron StroCare Suite™)

  • Mar

    MFDS Class 3 approval for Stroke Triage SW
    (Heuron ELVO)
    Selected as an outstanding company by the PoC (Proof of Concept) Program

  • Jan

    MFDS Class 2 approval for Dementia SW
    (Heuron Brain PET)

  • 2022

    Aug

    Clinical trial with Mass General Brigham
    (Stroke Triage SW)

  • Jul

    FDA approval for Parkinson’s SW
    (Veuron-Brain-mN1)
    Clinical trial with 3 hospitals for Parkinson’s Neuromelanin Certified for ISO 27001, ISO 27799

  • May

    MFDS Class 3 approval for Stroke Triage SW
    (Heuron ASPECTS)

  • Feb

    FDA approval for Dementia SW
    (Heuron Beta Amyloid)

  • Jan

    MFDS Class 3 approval for Stroke Triage SW
    (Heuron ICH)

  • 2021

    Nov

    MDSAP (Medical Device Single Audit Program) Certified Won the Minister of Health and Welfare Award for Health Industry Promotion Health and Medical Technology Commercialization MFDS Class 2 approval for Dementia SW
    (Heuron AD)

  • Oct

    Research MOU with Fraunhofer MEVIS, Germany

  • Jul

    Certified for ISO 13485

  • May

    CE approval for Parkinson’s SW, Dementia SW, Stroke SW
    (Veuron-Brain-mN1, Veuron-Brain-cIS, Veuron-Brain-pAb, Heuron IPD)
    Series C Investment ($11.5M)

  • Apr

    MFDS Class 3 approval for Parkinson’s SW
    (Heuron IPD)

  • Jan

    FDA approval for Dementia SW
    (Veuron-Brain-pAb)

  • 2020

    Dec

    Multi-institute clinical results for Parkinson’s SW
    (Heuron IPD, formal mPDia)

  • Nov

    Appointed as one of the 1,000 National Representatives of Innovative Company

  • Jul

    Series B Investment ($11.7M) KFDA approval and the 3rd Breakthrough Technology for Parkinson’s SW
    (Heuron IPD, formal mPDia)

  • 2019

    Jul

    Series A Investment ($2.3M)

  • 2017

    2017

    Foundation of Heuron Co., Ltd.

  • 01

    Developed Korea’s first NCCT-based comprehensive AI solution to support fast triage for acute stroke.
  • 02

    Innovative MRI-based AI solution
    developed to facilitate the diagnosis of
    Parkinson’s disease.
  • 03

    Data labeling process performed by
    experienced neurologists from
    university hospitals.
  • 04

    Segmentation template developed
    based on expert knowledge.
    Learning model with high sensitivity
    and specificity.
  • 05

    Extensive range of global patents in the challenging field of AI in brain imaging.
Our Partners

We collaborate with
world-renowned
medical institutions
based on our
recognized expertise.

Media Resources

Brain New Life, Together.
At Heuron, we are committed
to the sustainable happiness



for all.

TOP